Medical information Clinical review pending

Genetic Testing

ATP8A2 Gene Cerebellar Ataxia Mental Retardation and Dysequilibrium Syndrome Type 4 Genetic Test

Genetic test using Next-Generation Sequencing (NGS) to analyze the ATP8A2 gene for mutations associated with Cerebellar Ataxia, Mental Retardation, and Dysequilibrium Syndrome Type 4. Aids in diagnosing neurological disorders.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question

Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample: Blood sample, Extracted DNA, or One Drop of Blood on FTA Card.
Results: 3 to 4 Weeks. Confirm with the laboratory before booking.
Preparation: Provide a detailed clinical history of the patient. A genetic counseling session is recommended to create a family pedigree chart, especially if there is a family history of related conditions.

Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the ATP8A2 Gene Cerebellar Ataxia Mental Retardation and Dysequilibrium Syndrome Type 4 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

Insurer or scheme name & policy / member number
A clinician's request / prescription for the test
Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

Full name *

Mobile number *

+254

Insurer or scheme

Policy / member number (optional)

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

✓Unexplained motor coordination problems
✓Cognitive delays or mental retardation
✓Balance and equilibrium issues
✓Family history of neurological disorders
✓Suspected ATP8A2-related conditions

In plain language

What this test helps you understand

This test helps identify mutations in the ATP8A2 gene, which are associated with specific neurological disorders. It can aid in confirming a diagnosis, understanding the genetic basis of a condition, and informing family planning and genetic counseling.

The ATP8A2 Gene Cerebellar Ataxia Mental Retardation and Dysequilibrium Syndrome Type 4 NGS Genetic DNA Test is a diagnostic tool used to understand certain neurological conditions. This test uses Next-Generation Sequencing (NGS) technology to examine the ATP8A2 gene. Mutations in this gene are linked to neurological disorders, including cerebellar ataxia and mental retardation. Early and accurate diagnosis can help improve patient management and family planning. This test detects mutations in the ATP8A2 gene, which can cause motor coordination problems, cognitive impairments, and balance difficulties. Identifying these mutations allows healthcare providers to suggest appropriate treatment and management strategies. Results will be interpreted by a qualified medical geneticist, who will discuss the implications, potential treatment options, and follow-up actions. Discussing the results with a neurologist or genetic counselor is recommended for a complete understanding.

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

Speak with us

We check the test and answer your questions before collection.

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

Understand your report

A counselor helps you understand the result and the next steps.

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →

PreparationProvide a detailed clinical history of the patient. A genetic counseling session is recommended to create a family pedigree chart, especially if there is a family history of related conditions.

SampleBlood sample, Extracted DNA, or One Drop of Blood on FTA Card.

MethodologyNext-Generation Sequencing (NGS) of the ATP8A2 gene.

PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.

This test specifically analyzes the ATP8A2 gene. It may not detect mutations in other genes that can cause similar symptoms. Confirm with the laboratory before booking.

Read your report

What common result terms mean

TermPlain-language meaning

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.

NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.

VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.

Questions people ask

Frequently asked questions

This is a neurological disorder characterized by problems with movement coordination (ataxia), cognitive impairment (mental retardation), and balance issues (dysequilibrium), often linked to mutations in the ATP8A2 gene.

Individuals with symptoms like unexplained motor coordination problems, cognitive delays, balance issues, or a family history of similar neurological disorders should consider this test.

Results are interpreted by a medical geneticist. They will explain the findings and their implications. Discussing the results with your doctor or a genetic counselor is essential.

A blood sample, extracted DNA, or a single drop of blood on an FTA card is required.

The turnaround time is typically 3 to 4 weeks. Confirm with the laboratory before booking.

No, this test specifically looks for mutations in the ATP8A2 gene, which causes one specific type of ataxia and related syndromes. Other genes can cause different types of ataxia.

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

ACMG/AMP technical standards for sequence variant interpretation
ClinGen curation and gene–disease validity frameworks where applicable
LOINC-coded reporting for interoperable results
ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

Last updated: September 27, 2026
Medical review: not yet completed
Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Chat on WhatsApp